Nifedipine vs. enalapril in treatment of hypertensive patients with glucose intolerance.
To compare the metabolic effects of nifedipine and enalapril, we studied 21 obese patients (BMI of 31.6 +/- 1.1) with mild-to-moderate hypertension and glucose intolerance. None of the patients were receiving insulin or hypoglycemic agents. After a washout period of 15 days, blood pressure was recorded and fasting blood glucose, insulin, and lipid concentrations were determined. At random, 11 patients were started on nifedipine and 10 patients on enalapril. At the 90th day of treatment, clinical and laboratory tests were again performed. Both of the drugs reduced blood pressure values comparably. No significant variation of metabolic parameters was found after 90 days of treatment in the enalapril group. In the nifedipine group, the fasting insulin level was decreased and the glucose/insulin ratio was significantly increased, suggesting an improvement in insulin sensitivity; moreover, total plasma cholesterol was significantly reduced. Enalapril and nifedipine seem to be effective and safe drugs in the treatment of hypertensive subjects with obesity and glucose intolerance. Nifedipine can ameliorate insulin resistance and the lipid state.
Andronico
G
G
Chair of Internal Medicine, University of Palermo, Italy.
Piazza
G
G
Mangano
M T
MT
Mule
G
G
Carone
M B
MB
Cerasola
G
G
D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D008875:Middle Aged; D009543:Nifedipine / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications
D001786:Blood Glucose; D007328:Insulin; D004656:Enalapril; D002784:Cholesterol; D009543:Nifedipine; D005947:Glucose